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Abstract
Background: Breast cancer survivors are at high risk for fracture due to cancer treatment-induced bone loss, however,
data is scarce regarding the scope of this problem from an epidemiologic and health services perspective among
Chinese women with breast cancer.
Methods: We designed a cross-sectional study comparing prevalence of vertebral fractures among age- and BMI-
matched women from two cohorts. Women in the Breast Cancer Survivors cohort were enrolled from a large cancer
hospital in Beijing. Eligibility criteria included age 50–70 years, initiation of treatment for breast cancer at least
5 years prior to enrollment, and no history of metabolic bone disease or bone metastases. Data collected
included sociodemographic characteristics; fracture-related risk factors, screening and preventive measures;
breast cancer history; and thoracolumbar x-ray. The matched comparator group was selected from participants
enrolled in the Peking Vertebral Fracture Study, an independent cohort of healthy community-dwelling
postmenopausal women from Beijing.
Results: Two hundred breast cancer survivors were enrolled (mean age 57.5 ± 4.9 years), and compared with 200
matched healthy women. Twenty-two (11%) vertebral fractures were identified among breast cancer survivors
compared with 7 (3.5%) vertebral fractures in the comparison group, yielding an adjusted odds ratio for vertebral
fracture of 4.16 (95%CI 1.69–10.21, p < 0.01). The majority had early stage (85.3%) and estrogen and/or progesterone
receptor positive (84.6%) breast cancer. Approximately half of breast cancer survivors reported taking calcium
supplements, 6.1% reported taking vitamin D supplements, and only 27% reported having a bone density scan since
being diagnosed with breast cancer.
Conclusions: Despite a four-fold increased odds of prevalent vertebral fracture among Chinese breast cancer survivors
in our study, rates of screening for osteoporosis and fracture risk were low reflecting a lack of standardization of care
regarding cancer-treatment induced bone loss.
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Background
Breast cancer incidence worldwide has risen by 20% and
mortality rates by 14% since 2008, with the bulk of this
increase sustained by women in low- and middle-
income countries (LMICs) due to increasing life expect-
ancy, urbanization, and adoption of Western lifestyles
[1]. Although incidence rates have traditionally been low
in Asia compared with the U.S. or Europe, due to the
sheer population of many Asian countries, the absolute
numbers of women with breast cancer in this region has
risen dramatically [2].
Several studies have shown that women with breast
cancer are at increased risk for osteoporosis and fracture
[3–5]. This is largely attributable to the negative impact
of breast cancer treatments on skeletal health, which oc-
curs through decreased estrogen exposure [6, 7]. The
majority of such studies have been carried out in the
U.S. and Europe, where most women are postmeno-
pausal at the time of diagnosis and approximately 75%
of patients have hormone-receptor positive disease [8].
By contrast, a nation-wide epidemiologic study found
that the average age at breast cancer diagnosis in China
is approximately 10 years earlier than in the West, and
only 57.4% of women with breast cancer had hormone-
receptor positive disease [9].
Because of these differences in epidemiology, risk fac-
tors for fracture may be significantly different among
Chinese breast cancer survivors, and cannot simply be
extrapolated from studies in U.S. and European popula-
tions. Furthermore, in China, as in many other LMICs,
the infrastructure to monitor and manage osteoporosis
and fracture is severely limited, with scarce access to
dual-energy x-ray absorptiometry (DXA)—the gold-
standard for bone mineral density assessment—outside
of large tertiary care centers in major cities [10].
In order to quantify the scope of this problem and
identify potential health services gaps, we designed a
cross-sectional study to measure the prevalence of verte-
bral fractures among a cohort of breast cancer survivors
in Beijing, and compared our data with fracture preva-
lence among community-dwelling healthy women in
Beijing selected from a pre-existing cohort called the
Peking Vertebral Fracture (PK-VF) Study, and hypothe-
sized that vertebral fracture prevalence would be signifi-
cantly higher among our cohort of breast cancer
survivors.
Methods
Study design
We conducted a cross-sectional study comparing verte-
bral fracture rates and risk factors for fracture among
two cohorts in Beijing, China: breast cancer survivors
currently receiving care at a single large cancer center,
and an age- and body mass index (BMI)-matched group
of community-dwelling healthy women recruited as part
of a pre-existing epidemiological study of vertebral frac-
ture prevalence in Beijing. This study was reviewed and
approved by the institutional review board of the Cancer
Hospital, Chinese Academy of Medical Sciences and the
human investigations committee of Yale School of Medi-
cine prior to initiation.
Sample
Breast cancer survivors cohort
All breast cancer survivors receiving care at the
Cancer Hospital, Chinese Academy of Medical Sci-
ences (CHCAMS) from April 1, 2013 – August 31,
2014 were eligible for this study if they met the fol-
lowing criteria: 1) age 50–70 years, 2) initiated breast
cancer treatment at least 5 years prior to enrollment.
Exclusion criteria included: 1) initiated breast cancer
therapy within last 5 years, 2) history of bone metas-
tases, 2) osteoporosis or osteoporosis therapy prior to
breast cancer diagnosis, 3) metabolic or inherited
bone disease, 4) corticosteroid or anticonvulsive ther-
apy for > 6 months or within the last 12 months, 5)
conditions leading to secondary osteoporosis (rheuma-
toid arthritis/connective tissue disease, chronic liver
or kidney disease, malabsorption, inflammatory bowel
disease, poorly controlled hyperthyroidism). Initially
women were recruited by screening the CHCAMS
medical database for women diagnosed with breast
cancer at CHCAMS prior to January 1, 2008. Poten-
tially eligible women were contacted via telephone
and invited to participate in the study. However due
to the low success rate of this method during the first
month, we switched to a physician referral recruit-
ment approach where all patients presenting for fol-
low up in the breast cancer clinic who met eligibility
criteria were referred to the study physician. The
study physician met with each potential participant,
confirmed eligibility, explained the study purpose,
procedures and risks and benefits, and obtained writ-
ten informed consent.
PK-VF cohort
Details regarding the recruitment of the PK-VF Study
have been described previously [11]. This study recruited
a total of 1724 postmenopausal community-dwelling
Chinese women in 2008 from seven districts of Beijing,
aged 47–108 years. Investigators collected detailed data
regarding sociodemographic and clinical characteristics,
osteoporosis and fracture-related history and risk
factors, thoraco-lumbar x-rays, and serologic samples.
For the purposes of this study, we randomly selected an
age- and BMI-matched sample of women from the PK-
VF cohort.
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Measures
Breast cancer survivors cohort
Sources of data for each participant included a self-
administered study questionnaire, a medical chart re-
view form completed by the study physician, thoracol-
umbar x-ray, and fasting serum sample. The study
questionnaire consisted of 19 questions that addressed
sociodemographic characteristics (age, education level,
smoking history, and current alcohol use), history of
and risk factors for fracture (height, weight, history of
a fall within the last year, parental history of fracture,
personal history of fracture, bone mineral density test-
ing or diagnosis of low bone mineral density since
breast cancer diagnosis, calcium or vitamin D supple-
ment use), and reproductive health history (age at
menarche, parity, age at menopause if applicable, and
history of hormone replacement therapy use). Data
collected from the medical chart included date of
breast cancer diagnosis, stage at diagnosis, pathologic
diagnosis, estrogen- and progesterone-receptor status,
and HER-2 receptor status. Initial breast cancer treat-
ment history was recorded including type of surgery,
and use of radiation therapy, chemotherapy, and/or
endocrine therapy [i.e. selective estrogen-receptor
modulators (SERMs), aromatase inhibitors (AIs), go-
nadotropin releasing hormone (GnRH) agonists, ovari-
ectomy]. Data regarding history of recurrence were
also obtained.
Thoracic and lumbar lateral spine x-rays were per-
formed to identify prevalent vertebral fractures at the
diagnostic imaging department of CHCAMS. For each
participant, presence of vertebral fracture was ascer-
tained by two radiologists using the validated Genant
semi-quantitative technique [12]. In this method, ver-
tebrae T4-L4 are graded on visual inspection and
without direct measurement at normal (grade 0),
mildly deformed (grade 1, approximately 20–25% re-
duction in anterior, middle, and/or posterior height
and a reduction in area of 10–20%), moderately de-
formed (grade 2, approximately 25–40 reduction in
any height and a reduction in area 20–40%), and se-
verely deformed (grade 3, approximately 40% reduc-
tion in any height and area).
Fasting serum samples were collected from each par-
ticipant and stored at -80 °C until batch testing at the
end of the study period. We tested 25-hydroxy vitamin
D (25OHD) levels, and the bone formation marker pro-
collagen type 1 N propeptide (P1NP), and the bone re-
sorption marker serum β-c-terminal telopeptide of type
1 collagen (CTx) to assess bone metabolism. All bio-
markers were assayed at the Di’an laboratory in Beijing,
China using an automated Roche electrochemilumines-
cence immunoassay (cobas e 601, Roche Diagnostics,
Basel, Switzerland).
PK-VF cohort
For each participant, data were extracted from the PK-
VF Study database regarding participant age, BMI, edu-
cation level, parity, menstrual history, smoking, alcohol
use, history of bilateral ovariectomy, parental history of
fracture, personal history of fracture, and calcium sup-
plement use. As part of the PK-VF Study, prevalent ver-
tebral fractures were also ascertained using lateral
thoracolumbar x-ray, and evaluated by two experienced
radiologists using the Genant semi-quantitative method
described above. Serum biomarkers, CTx, P1NP, and
25OHD, were batch tested at the central laboratory of
the Department of Endocrinology, Peking Union Med-
ical College Hospital, by an automated Roche electro-
chemiluminescence immunoassay (Modular Analytics
E170; Roche Diagnostics, Basel Switzerland) [11].
Data analysis
All statistical analyses were performed using Stata Inter-
cooled 13 (StataCorp, College Station, TX). Descriptive
statistics were used to report the sociodemographic
characteristics, frequency of fracture, and fracture-
related risk factors in the two cohorts. Categorical vari-
ables were compared using χ2 or Fisher’s exact test, and
continuous variables were compared using the t-test.
Univariate logistic regression was further used to calcu-
late the odds of vertebral fracture based upon breast
cancer status, age, BMI, level of education, parity, per-
sonal history of fracture, calcium supplement use, and
25OHD level. We fit the multivariable model using
backward elimination beginning with all variables that
were significant (p-value < 0.10) in the univariate ana-
lyses (breast cancer survivor status, age, parity, calcium
supplement use) [13]. To obtain a parsimonious model,
we removed non-significant variables (p > 0.05) one at a
time beginning with the least significant; in each step,
remaining parameter estimates remained largely un-
changed (< 20%). Among the cohort of breast cancer
survivors, we further performed subgroup analyses based
upon fracture status using χ2, Fisher’s exact test, and the
t-test as appropriate.
Results
Sociodemographic, reproductive and fracture-associated
characteristics
In total, 200 survivors of breast cancer were enrolled
and 200 matched healthy women were selected from the
PK-VF cohort. The mean age of both cohorts was 57.5 ±
4.9 years and over half of women had a BMI above
24 kg/m2 (Table 1). Women in the breast cancer cohort
were more highly educated and smoking and alcohol use
were rare among both cohorts. Fewer women with
breast cancer self-reported a personal history of fracture
(10.5 v. 21%, p = 0.004). Among breast cancer survivors
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the most commonly reported site of fracture was the
wrist (8/21, 38.1%). One patient reported a history of hip
fracture and only one self-reported a history of vertebral
fracture. Other reported fracture sites included the
ankle, lower leg, foot, finger, coccyx, knee, toes, and ribs.
Thirty-three percent (6/18) of fractures were reported as
low-trauma fractures. More breast cancer survivors re-
ported using calcium supplements (49 v. 36.9%, p =
0.015). Only 12/200 (6%) of women with breast cancer
reported using vitamin D supplements.
Vitamin D status and bone turnover markers
Mean levels of 25OHD were significantly higher among
the breast cancer survivors compared with women in
the PK-VF Study (20.3 ± 7.8 v. 13.3 ± 5.7, p < 0.001)
(Table 1). Even so, 113/196 (58.2%) of women with
breast cancer met criteria for 25OHD deficiency (<
20 ng/mL), and 61/196 (35.2%) met criteria for 25OHD
insufficiency (20-29 ng/mL). By contrast, no significant
differences in mean levels of bone turnover makers were
noted between the two groups. The correlation
coefficient between CTx and P1NP was 0.72 (p < 0.001)
among breast cancer survivors, and 0.78 (p < 0.001)
among the PK-VF cohort demonstrating appropriate
coupling of bone formation and resorption in both
groups.
Vertebral fractures
Table 2 demonstrates the total number of women in the
breast cancer survivors cohort (22/200, 11%) and PK-VF
cohort (7/200, 3.5%) with prevalent vertebral fractures.
Several women had more than one fracture, and the
total number of vertebral fractures identified by thora-
columbar x-ray was also significantly greater among
breast cancer survivors (47 v. 9 fractures, p < 0.001).
Breast cancer survivors were more likely to have mul-
tiple fractures as well as higher grade fractures. The odds
of having a vertebral fracture among breast cancer survi-
vors compared with their healthy counterparts was 3.41
(95%CI 1.42–8.17, p = 0.006) (Table 3). In the multivari-
able model, the odds of vertebral fracture among breast
cancer survivors was 4.16 (95%CI 1.69–10.21, p = 0.002)
compared with women in the PK-VF cohort.
Characteristics of breast cancer survivors cohort
Table 4 details the characteristics of the cohort of breast
cancer survivors based upon fracture status, including
breast cancer-related characteristics. The average dur-
ation of breast cancer at the time of enrollment was 6.3
± 1.9 years. Approximately 85% of women were
Table 1 Sociodemographic, Reproductive, and Fracture-
Associated Characteristics of BCS and PK-VF Study Cohorts
Variable BCS Cohort PK-VF Cohort
Age years 57.5 ± 4.9 57.5 ± 4.9
BMI kg/m2 24.8 ± 3.7 24.7 ± 3.2
Education ≥ High School 156/200 (78)c 91/197 (46.1)
Smoking, Ever 6/200 (3) 5/200 (2.5)
Current Alcohol Use 11/200 (5.5) 8/200 (4.0)
Menarche years 14.4 ± 2.0b 15.1 ± 2.4
Menopause years 49.4 ± 4.0 49.6 ± 3.5
Parity
0 2/200 (1%) 2/190 (1.6)
1 137/200 (68.5)b 102/190 (53.7)
≥ 2 61/200 (30.5)a 85/190 (44.7)
Fall in Past Year 31/198 (15.7) –
Parental Fracture History 20/188 (10.6) 31/200 (15.5)
Personal Fracture History 21/200 (10.5)b 42/200 (21)
Calcium Supplement Use 96/196 (49.0)a 73/198 (36.9)
Vitamin D Supplement Use 12/200 (6.0%) –
CTx ng/mL 0.458 ± 0.211 0.441 ± 0.199
P1NP ng/mL 61.1 ± 30.4 56.3 ± 24.6
25OHD ng/mL 20.3 ± 7.8c 13.3 ± 5.7
Values for continuous variables are reported as mean ± SD and for categorical
values as n/N(%)
PK-VF Peking Vertebral Fracture study, BCS breast cancer survivors, CTx serum
β-c-terminal telopeptide of type 1 collagen, P1NP pro-collagen type 1 N
propeptide, 25OHD 25-hydroxy vitamin D, kg kilograms, m meters, ng
nanograms, mL milliliters
a < .05
b < .01
c < .001
Table 2 Vertebral Fracture Results for BCS and PK-VF Study
Cohorts
Variable BCS Cohort PK-VF Cohort
Individuals with VF n/N(%) 22/200 (11%)§ 7/200 (3.5%)
Grade 1a, b 13 5
Grade 2 12§ 2
Grade 3 2 0
VFs per Individual median(range) 1(1–10) 1(1–2)
Total Number of VF N 47¥ 9
Grade 1 19* 7
Grade 2 25¥ 2
Grade 3 3 0
VF vertebral fracture, PK-VF Peking Vertebral Fracture Study, BCS breast
cancer survivors
* < .05
§ < .01
¥ < .001
a Please note that because some individuals have multiple fractures of
different grades, the number of individuals with grade 1, grade 2 and grade 3
fractures add up to more than 22
b Vertebral Fractures were classified using the Genant Semi-Quantitative technique.
In this method, vertebrae T4-L4 are graded as normal (Grade 0), mildly deformed
(Grade 1, approximately 20–25% reduction in anterior, middle, and/or posterior
height and a reduction in area of 10–20%), moderately deformed (Grade 2,
approximately 25–40 reduction in any height and a reduction in area 20–40%), and
severely deformed (Grade 3, approximately 40% reduction in any height and area)13
Hsieh et al. BMC Cancer  (2018) 18:104 Page 4 of 9
diagnosed at early stage (stage I or II), and a similar pro-
portion had hormone receptor positive disease on path-
ology and underwent some form of endocrine therapy
during the course of treatment, including SERMS [tam-
oxifen (56/70) and/or toremifene (21/70)], AIs [Anastro-
zole (55/90), Letrozole (23/90), and/or Exemestane (13/
90)] and GnRH agonists [Goserelin (1/2) and Leuprolide
(1/2)]. Sixteen women underwent ovariectomy as part of
breast cancer therapy. The average length of treatment
with SERMS was 50.5 ± 21.4 months, and the average
length of treatment with AIs was 58.9 ± 17.9 months.
Forty-three percent of women were postmenopausal at
the time of breast cancer diagnosis, of whom only 29.6%
reported having had a DXA scan since being diagnosed.
Of the 90 women who were treated with AI therapy,
only 30% reported having had a DXA scan. Approxi-
mately 16% of breast cancer survivors reported a fall
within the last year, and 49% reported taking a calcium
supplement.
Stratified analyses based upon fracture status, showed
that women with fracture were older and therefore more
likely to be postmenopausal at the time of diagnosis
(63.6 v. 40.1%, p = 0.036), and had a lower level of educa-
tion (59.1 v. 80.3% with ≥ high school education, p =
0.023). Although our sample was not powered to for-
mally evaluate differences in fracture status based upon
treatment class, we observed that vertebral fractures
were detected among 7/74 (9.4%) of women receiving
AIs only, 5/54 (9.3%) receiving SERMs only, 1/16 (6.3%)
who had received both an AI and SERM, and in 3/16
(18.8%) women who had been treated with ovariectomy.
Of note, all three of the ovariectomized women with
fractures were premenopausal at the time of diagnosis
and had concurrently been treated with a SERM. 8/54
(14.8%) of women who received radiation treatment had
a vertebral fracture, however 7 of those women were
also concurrently treated with some form of endocrine
therapy.
Levels of 25OHD, bone turnover markers, and treat-
ment patterns did not vary based upon fracture status.
Discussion
Our study is the first to directly measure rates of frac-
ture among breast cancer survivors in China compared
to age- and BMI-matched healthy women. We found
that history of breast cancer was associated with a four-
fold increased odds of prevalent vertebral fractures. Fur-
thermore, breast cancer survivors with fractures were
more likely to have multiple fractures and higher grade
fractures compared to their healthy counterparts. Finally,
rates of DXA screening for bone disease were low
among women with breast cancer, even among those
who were postmenopausal at the time of diagnosis or
treated with AIs, factors known to increase risk for
fracture.
Rates of fractures have traditionally been higher in
Europe and the U.S. compared to China [14]. Therefore,
it is consistent that absolute prevalence of fractures in
both of our cohorts were lower compared with previous
studies among women from Caucasian populations.
However, recent studies have also shown that rates of
fracture are rapidly increasing in China due to
urbanization and adoption of Western lifestyles [15]. In
our study, the magnitude of the increased odds for frac-
ture seen among breast cancer survivors is roughly on
par with prior findings. Kanis et al., found that preva-
lence of vertebral fractures among women with soft-
tissue breast cancer recurrence (without skeletal metas-
tases) was six-fold higher compared with healthy con-
trols or women newly diagnosed with breast cancer [4].
However, their study population was acutely ill and
mean age was 2 years older than our cohort, whereas
our cohort included predominantly recurrence-free
breast cancer survivors.
To our knowledge only one prior study has been pub-
lished from mainland China examining this issue [16].
This study retrospectively compared 70 postmenopausal
women with breast cancer receiving AI therapy, with 52
women receiving tamoxifen, and 89 women who were
not treated with endocrine therapy at a single institution.
The authors found that women on AIs had an increased
incidence of fractures (12.9%) compared with those not
treated with endocrine therapy (1.1%, p = 0.001). By
Table 3 Logistic Regression Analysis: Odds of Vertebral Fracture
among Women in the BCS and PK-VF Study Cohorts, Combined
(N = 400)
Variable Univariate Model Multivariable Model
OR 95%CI OR 95%CI
Breast Cancer Survivor 3.41 1.42–8.17c 4.16 1.69–10.21c
Age years 1.08 1.01–1.17c 1.10 1.02–1.20b
BMI kg/m2 0.90 0.78–1.03 – –
Education ≥High School 0.85 0.39–1.83 – –
Parity 1.49 0.93–2.37a – –
Age of Menarche years 1.08 0.92–1.27 – –
Personal History of Fracture 0.60 0.18–0.12 – –
Calcium Supplement Use 0.48 0.21–1.12a 0.37 0.15–0.89b
25OHD Level ng/mL 1.00 0.95–1.05 – –
Continuous variables: Age, BMI, Parity, Age of Menarche, 25OHD level.
Categorical variables: Breast Cancer Survivor (reference: Peking Vertebral
Fracture Study participant), Education (reference: ≤middle school), Personal
History of Fracture (reference: no history of fracture), Calcium Supplement Use
(reference: no supplement use)
OR odds ratio, CI confidence interval, BMI body mass index, 25OHD 25-hydroxy
vitamin D
a < 0.1
b < .05
c < .01
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Table 4 Characteristics of BCS Cohort, Overall and by Fracture Status
Variable Overall No Fracture Fracture
Age years 57.5 ± 4.9 57.1 ± 4.8 60.0 ± 5.2b
BMI kg/m2 24.8 ± 3.7 24.9 ± 3.7 23.8 ± 3.3
Education ≥ High
School
156/200 (78) 143/178 (80.3) 13/22 (59.1)a
Menarche years 14.4 ± 2.0 14.5 ± 1.9 14.5 ± 2.1
Menopause years 49.4 ± 4.0 49.4 ± 4.2 49.2 ± 2.2
Parity
0 2/200 (1) 2/178 (1.1) 0/22 (0)
1 137/200 (68.5) 126/178 (70.8) 11/22 (50)a
≥ 2 61/200 (30.5) 50/178 (28.1) 11/22 (50)a
Smoking, Ever 6/200 (3) 6/178 (3.4) 0/22 (0)
Current Alcohol Use 11/200 (5.5) 11/178 (6.2) 0/22 (0)
Fall in Past Year 31/198 (15.7) 28/176 (15.9) 3/22 (13.6)
Parental Fracture History 20/188 (10.6) 18/167 (10.8) 2/21 (9.5)
Personal Fracture History 21/200 (10.5) 19/178 (10.7) 2/22 (9.1)
Calcium Supplement 96/196 (49) 88/174 (50.6) 8/22 (36.4)
DXA Since Diagnosis 54/200 (27) 44/178 (24.7) 10/22 (45.5)a
Low BMD Since
Diagnosis
24/195 (12.3) 22/173 (12.7) 2/22 (9.1)
CTx ng/mL 0.458 ± 0.211 0.457 ± 0.209 0.463 ± 0.227
P1NP ng/mL 61.1 ± 30.4 61.3 ± 30.1 58.9 ± 33.2
25OHD ng/mL 20.3 ± 7.8 20.5 ± 7.6 19.0 ± 9.7
Postmenopausal at
Diagnosis
81/189 (42.9) 67/167 (40.1) 14/22 (63.6)a
Duration of Breast
Cancer
6.3 ± 1.9 6.4 ± 2.0 6.1 ± 1.6
BrCa Stage at
Diagnosis
I 77/183 (42.1) 69/162 (42.6) 8/21 (38.1)
II 79/183 (43.2) 69/162 (42.6) 10/21 (47.6)
III 27/183 (14.8) 24/162 (14.8) 3/21 (14.3)
Hormone Receptor
Status
ER+/PR+ 113/186 (60.1) 100/164 (61) 13/22 (59.1)
ER+/PR- 11/186 (5.9) 10/164 (6.1) 1/22 (4.6)
ER-/PR+ 33/186 (17.6) 30/164 (18.3) 3/22 (13.6)
ER-/PR- 29/186 (15.4) 24/164 (14.6) 5/22 (22.7)
HER2 Receptor
Positive
38/183 (20.8) 35/161 (21.7) 3/22 (13.6)
Surgery 187/187 (100) 165/165 (100) 22/22 (100)
Radiation
Therapy
53/182 (29.1) 45/160 (28.1) 8/22 (36.4)
Chemotherapy 153/185 (82.7) 135/163 (82.8) 18/22 (81.8)
Endocrine
Therapy
158/189 (84) 141/167 (84.4) 17/22 (77.3)
SERM 70/188 (37.2) 64/166 (38.6) 6/22 (27.3)
Aromatase
Inhibitor
90/189 (47.6) 82/167 (49.1) 8/22 (36.4)
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contrast, incidence of fractures among those treated with
tamoxifen did not differ (1.9%, p = 0.372) compared with
those not treated with endocrine therapy. Unfortunately,
this study is significantly limited by the lack of descrip-
tion regarding how osteoporotic fractures were defined
and measured, and sparse risk factor data.
Three studies from Taiwan using retrospective data
from their National Insurance Research Database have
also examined this issue among ethnically Chinese
women with breast cancer. Tzeng et al. reported tamoxi-
fen use was associated with reduced risk of osteoporotic
fractures, however did not specify whether women in
their cohort were pre- or postmenopausal [17]. Chang et
al. studied fracture risk in young breast cancer patients
and found that those receiving AIs, radiotherapy, or
Herceptin were at increased risk for future fracture [18].
Tsa et al. showed that age-specific hazard ratio for frac-
ture was higher for breast cancer patients < 50 years of
age, both for traumatic and non-traumatic fractures [19].
However, these studies are all based upon insurance
claims data and rely on International Conference for the
Ninth Revision of the International Classification of Dis-
eases (ICD-9) codes for diagnosis. Validation of the diag-
nostic codes was not described therefore further studies
are needed to confirm these findings in prospective co-
horts. Our data provide a meaningful comparison to
these studies given the differences in lifestyle, nutrition,
medical care and environmental exposures among
women in mainland China compared with Taiwan, and
provides direct assessment of fracture associated risk
factors not available from insurance claims data.
Previous epidemiologic studies from Asian countries
have demonstrated that the peak age of breast cancer
diagnosis occurs approximately a decade earlier among
Asian women compared with their Western counter-
parts [20, 21]. The age and menopausal status at diagno-
sis of our cohort are consistent with data from a
nationally representative sample of 4211 Chinese women
diagnosed with breast cancer (mean age at diagnosis =
48.7 ± 10.5 years, 62.9% premenopausal). Because the
vast majority of studies on this subject have been con-
ducted in Western populations, the long-term impact of
breast cancer treatment on bone health among Asian
women remains unknown. Furthermore, less is known
about the long-term risk for fracture among premeno-
pausal women and guidelines cannot simply be extrapo-
lated from studies for postmenopausal women with
breast cancer.
As a population, Chinese women undergoing treat-
ment for breast cancer will become vulnerable to frac-
ture at a younger age relative to their Western
counterparts, during a period when comparatively little
attention is typically given to fracture risk reduction.
Furthermore, even when increased fracture risk is identi-
fied, management algorithms are less straightforward for
premenopausal women compared with postmenopausal
women. In 2012, Hadji et al. published a review of the
complexities of cancer treatment-induced bone loss
(CTIBL) among premenopausal women, and proposed a
framework with which to approach this problem includ-
ing indications for DXA screening and calcium and vita-
min D supplementation [22]. However, in China, as in
other rapidly modernizing Asian countries, lack of ac-
cess to DXA and osteoporosis specialists is common,
and presents a barrier to comprehensive fracture risk as-
sessment. In 2013, there were only an estimated 0.0046
DXA machines per 10,000 individuals in China, which is
far below the density (0.11 per 10,000 population) rec-
ommended by the International Osteoporosis Founda-
tion [10]. The lack of DXA access at even the highest-
tier cancer centers, including CHCAMS, also suggests a
fundamental lack of recognition and prioritization at the
health systems level regarding the long-term impact of
CTIBL on health outcomes.
From a practice perspective, our study underscores the
importance of awareness of fracture risk associated with
breast cancer therapies both on the part of the provider
and patient. Although fracture rates were relatively high,
due to the asymptomatic nature of most vertebral frac-
tures, the vast majority of women and their providers
were not aware of these fractures. While guidelines exist
in China for screening and management of CTIBL, it is
apparent that gaps remain in terms of uptake of these
recommendations in practice. Indeed, among breast
Table 4 Characteristics of BCS Cohort, Overall and by Fracture Status (Continued)
Variable Overall No Fracture Fracture
GnRH agonist 2/189 (1.1) 2/167 (1.2) 0/22 (0)
Ovariectomy 16/189 (8.5) 13/167(7.8) 3/22 (13.6)
Recurrence 2/185 (1.1) 2/162 (1.2) 0/22 (0)
Values for continuous variables are reported asmean± SD and for categorical values as n/N(%)
PK-VF Peking Vertebral Fracture Study, BCS breast cancer survivors, DXA dual-energy x-ray absorptiometry, BMD bone mineral density, CTx serum β-c-terminal telopeptide of
type 1 collagen, P1NP pro-collagen type 1 N propeptide, 25OHD 25-hydroxy vitamin D, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor
receptor 2, SERM selective estrogen receptor modulator, GnRH gonadotropin releasing hormone
a < .05
b < .01
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cancer survivors with a prevalent vertebral fracture, less
than 50% had obtained a DXA scan. While 49% of breast
cancer survivors were on calcium supplements, only 9%
were taking vitamin D supplements. Given age and post-
menopausal status are known risk factors for fractures,
it is not surprising that overall, more fractures occurred
among women who were postmenopausal at the time of
diagnosis. However, it is important to note that 8/108
(7.4%) of breast cancer survivors who were premeno-
pausal at the time of diagnosis were also found to have
vertebral fractures, which underscores the excess risk for
fractures in this population. While studies have demon-
strated bisphosphonates may be effective for mitigating
CTIBL, such studies have not been powered to measure
impact on fracture rates [23–25].
Our study has several limitations that warrant men-
tion. First, the PK-VF cohort has a few key differences
compared with the breast cancer survivors cohort. It
was enrolled 5 years earlier than the breast cancer survi-
vors cohort, and carried out by a separate group of in-
vestigators and radiologists. However, the principal
investigator of the PK-VF was a collaborator on this
study and extensive care was taken to parallel the meth-
odologies of the two studies to ensure comparability of
findings. Second, although all breast cancer survivors
were > 50 years of age, at baseline 6.5% of women in the
breast cancer survivors cohort were not yet in meno-
pause. This group also had higher education levels, earl-
ier menarche, lower parity rates, lower personal fracture
history, higher rates of calcium supplement use, and
higher baseline 25OHD levels. During the design of our
study, to avoid potential bias due to overmatching, we
did not choose to match our controls based upon each
of these factors and instead, took them into account in
our regression analyses. As these characteristics would
have been expected to be associated with lower risk of
fracture, if anything, our findings would underestimate
the risk of fracture among Chinese breast cancer survi-
vors. Third, given the cross-sectional design of our
study, our data do not allow for calculation of incidence
rates of vertebral fracture over time, nor change in la-
boratory parameters. Our study was also not powered to
look for subgroup analyses based upon treatment regi-
men, therefore we are unable to provide formal compari-
sons of fracture rates by type of treatment or duration of
those treatments. Finally, our study population was lim-
ited to breast cancer survivors presenting for routine fol-
low up at a major cancer hospital in Beijing, and
therefore may not generalizable to all Chinese women
with breast cancer, nor to other regions of China.
Conclusion
In summary, our study found breast cancer survivors in
China have a four-fold increased odds of prevalent
vertebral fracture compared with age- and BMI-matched
healthy women. However, rates of screening for osteo-
porosis and fracture risk by DXA were low reflecting a
lack of standardization of care regarding screening, pre-
vention and treatment of this problem. Future longitu-
dinal studies are needed to elucidate the fracture risk
specific to women who are premenopausal at the time of
diagnosis and how risk relates to treatment regimens. Fi-
nally, infrastructure limitations such as lack of access to
DXA imaging at cancer hospitals remain important bar-
riers to timely intervention.
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